Ευρωπαϊκή Ένωση - Δανικά - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - linaclotide - irritabelt tarmsyndrom - lægemidler til forstoppelse - constella er indiceret til symptomatisk behandling af moderat til svær irritabel tarmsyndrom med forstoppelse (ibs-c) hos voksne.

Ευρωπαϊκή Ένωση - Δανικά - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - bimatoprost - glaucoma, open-angle; ocular hypertension - prostaglandin analogues, ophthalmologicals - reduktion af forhøjet intraokulært tryk i kronisk åbenvinklet glaukom og okulær hypertension (som monoterapi eller som supplerende terapi til beta-blokkere).

Ευρωπαϊκή Ένωση - Δανικά - EMA (European Medicines Agency)

abbvie deutschland gmbh co. kg - glecaprevir, pibrentasvir - hepatitis c kronisk - antivirale midler til systemisk anvendelse - maviret is indicated for the treatment of chronic hepatitis c virus (hcv) infection in adults and children aged 3 years and older. maviret coated granules is indicated for the treatment of chronic hepatitis c virus (hcv) infection in children 3 years and older.

Ευρωπαϊκή Ένωση - Δανικά - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - bimatoprost, timolol - glaucoma, open-angle; ocular hypertension - oftalmologiske - reduktion af intraokulært tryk (iop) hos patienter med åbenvinklet glaukom eller okulær hypertension, som ikke er tilstrækkeligt lydhør overfor aktuelle beta-blokkere eller prostaglandinanaloger.

Ευρωπαϊκή Ένωση - Δανικά - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - dexamethason - macular edema; uveitis - ophthalmologicals, other ophthalmologicals - ozurdex er indiceret til behandling af voksne patienter med macula ødem efter enten gren retinal-vene okklusion (brvo) eller central retinal-vene okklusion (crvo). ozurdex er indiceret til behandling af voksne patienter med betændelse i den bageste del af øjet viser sig som ikke-smittefarlige uveitis. ozurdex er indiceret til behandling af voksne patienter med synsnedsættelse på grund af diabetisk macula ødem (dme), som er pseudophakic, eller som anses for tilstrækkeligt lydhøre over for, eller uegnet til ikke-kortikosteroidbehandling.

Ευρωπαϊκή Ένωση - Δανικά - EMA (European Medicines Agency)

abbvie deutschland gmbh co. kg - ombitasvir, paritaprevir, ritonavir - hepatitis c kronisk - antivirale midler til systemisk anvendelse - viekirax er indiceret i kombination med andre lægemidler til behandling af kronisk hepatitis c (chc) hos voksne. for at hepatitis c virus (hcv) genotype specifikke aktivitet.

Ευρωπαϊκή Ένωση - Δανικά - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - risankizumab - psoriasis; arthritis, psoriatic - immunosuppressiva - plaque psoriasisskyrizi is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritisskyrizi, alone or in combination with methotrexate (mtx), is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (dmards). crohn's diseaseskyrizi is indicated for the treatment of adult patients with moderately to severely active crohn's disease who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy.

Ευρωπαϊκή Ένωση - Δανικά - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - atogepant - migræneforstyrrelser - aquipta is indicated for prophylaxis of migraine in adults who have at least 4 migraine days per month.

Ευρωπαϊκή Ένωση - Δανικά - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - epcoritamab - lymphoma, large b-cell, diffuse - antineoplastiske midler - tepkinly as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) after two or more lines of systemic therapy.

Ευρωπαϊκή Ένωση - Δανικά - EMA (European Medicines Agency)

abbvie deutschland gmbh co. kg - venetoclax - leukæmi, lymfocytisk, kronisk, b-celle - antineoplastiske midler - venclyxto in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. venclyxto in combination with rituximab is indicated for the treatment of adult patients with cll who have received at least one prior therapy. venclyxto monotherapy is indicated for the treatment of cll:- in the presence of 17p deletion or tp53 mutation in adult patients who are unsuitable for or have failed a b cell receptor pathway inhibitor, or- in the absence of 17p deletion or tp53 mutation in adult patients who have failed both chemoimmunotherapy and a b-cell receptor pathway inhibitor. venclyxto in combination with a hypomethylating agent is indicated for the treatment of adult patients with newly  diagnosed acute myeloid leukaemia (aml) who are ineligible for intensive chemotherapy.